Publications

Search our bibliography using the filters on the right-hand side.

Displaying 251 through 300 of 720 publications.

Harrigan (Zhang) K, Walton SM, Huang SP, Kumar VM, Chapman RH, Atlas SJ, Agboola FO, Ollendorf DA, Touchette DR. Long-term cost effectiveness of valbenazine and deutetrabenazine for tardive dyskinesia. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S184. doi: 10.1016/j.jval.2018.04.1257

Trantham L, Klein AB, Parikh RC, Kurosky S, Zhang Y, Levine CA, Kaye JA. Unresectable, locally advanced, stage III non-small cell lung cancer: real-world clinical characteristics, treatment patterns, and health care resource utilization in Europe. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S49. doi: 10.1016/j.jval.2018.04.289

Grimes R, Grant L, Kaur S, Brookes B, Bennett B. Review of frequently implemented patient reported outcomes in current prostate cancer clinical trials. Value Health. 2018 May 1;21(Suppl 1):S225. doi: 10.1016/j.jval.2018.04.1521

Talbird SE, Hogea CS, Meyers J, Carrico J, Buck PO. Cost-effectiveness of a 10-year revaccination with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (TDaP) vaccine among individuals with pre-existing asthma in the United States. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S153. doi: 10.1016/j.jval.2018.04.1062

Copley-Merriman K. Rare diseases: addressing the challenges in diagnosis, drug approval, and patient access - editorial. Value Health. 2018 May;21(5):491-2. doi: 10.1016/j.jval.2018.03.009

Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, Torgersen KM, Masters ET. Systematic Literature Review (SLR) of sequencing of Anaplastic Lymphoma Kinase (ALK) inhibitors in ALK-Positive Non-Small Cell Lung Cancer (NSCLC). Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S49-50. doi: 10.1016/j.jval.2018.04.291

Fernandez MM, Khan S, Mordin M, Copley-Merriman C, Mcbride D. Comparing literature review requirements for reimbursement submissions across the globe. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S108. doi: 10.1016/j.jval.2018.04.732

Kurosky S, Klein AB, Parikh RC, Trantham L, Zhang Y, Levine CA, Kaye JA. Clinical characteristics, treatment patterns, and health care resource utilization in unresectable, locally advanced, stage III non-small cell lung cancer: a medical record review study in the United States and Canada. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S49. doi: 10.1016/j.jval.2018.04.286

Ajmera MR, Meyers J. Economic burden of cardiometabolic disorders among patients with asthma. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 21, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S234. doi: 10.1016/j.jval.2018.04.1587

Peay H, Fischer R, Beaverson K, Morris C, Hesterlee SE, Ricotti V, Martin A, Rensch C, Wand H, Mansfield CA. Parent and adult patient attitudes about gene therapy as a therapeutic option for Duchenne Muscular Dystrophy. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S256.

Zhou X, Eid D, Gnanasakthy A. Methods for reporting the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) data in cancer clinical trials. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 21, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S226. doi: 10.1016/j.jval.2018.04.1528

Sluga-O'Callaghan M, Ansquer V, Frugier G, Mai C. Evolution of regulatory requirements for retrospective observational studies using medical records in Austria, Belgium, Italy, Netherlands and Switzerland. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S51. doi: 10.1016/j.jval.2018.04.425

Herring W, Gould IG, Zhang Y, Mladsi DM. The relationship between compliance and blindness prevention in economic models for diabetic retinopathy screening. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S161. doi: 10.1016/j.jval.2018.04.1209

Mahida S, Yunusa I, Bin Sawad A, Alsumali A. Systematic assessment of decision analytic models for the cost effectiveness of immunosuppressive agents used in kidney transplant patients. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May 1; 21(Supplement 1):S267. doi: 10.1016/j.jval.2018.04.1806

Mahida S, Alsumali A, Bin Sawad A. Price analysis of immunosuppressants which are approved by FDA as anti-rejection therapy for kidney transplantation in the United States. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May 1; 21(Supplement 1):S266. doi: 10.1016/j.jval.2018.04.1801

Pearson I, Rothwell B, Olaye A, Knight C. Economic modeling considerations for rare diseases. Value Health. 2018 May;21(5):515-24.

Mordin M, Buck PM, Castro C, Fernandez MM, Hollis KA, Ritchey ME. What does "Real World" evidence mean? A review of 2017 literature. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S108. doi: 10.1016/j.jval.2018.04.736

DeMuro C, Lewis S, Barrett A, Andersson FL. Assessing sleep impact in patients with nocturia disorder. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S267. doi: 10.1016/j.jval.2018.04.1816

Nagar SP, Parikh RC, Davis KL. Prescription opioid use among children and adolescents with asthma in the United States: national estimates from 2011 to 2015. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 21, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S237. doi: 10.1016/j.jval.2018.04.1602

Parikh RC, Klein AB, Kurosky S, Trantham L, Zhang Y, Levine CA, Kaye JA. Programmed cell death LIGAND-1 testing among patients with metastatic non-small cell lung cancer: a multinational medical record review study. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S50. doi: 10.1016/j.jval.2018.04.1821

Ritchey ME, Hollis KA, Hauber AB, Gilsenan A, Krueger WS. Reporting of "Benefit-Risk" studies for medical devices in published literature. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S175. doi: 10.1016/j.jval.2018.04.1167

Qin S, Coles T, Nelson L, McLeod L, Williams V, Williams N, Reaney M. CDFs and PDFs: comparing visual methods supporting responder thresholds in clinical trials. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 21, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl):S53. doi: 10.1016/j.jval.2018.04.442

Rupniewska E, Singer D, Khan S, Neighbors M, Chiarappa J, Obando C. Systematic literature review of real-world evidence on adherence with biologics in inflammatory bowel disease in the United States. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S87. doi: 10.1016/j.jval.2018.04.581

Rupniewska E, Singer D, Khan S, Neighbors M, Chiarappa J, Obando C. Systematic literature review of real-world evidence on persistence, switching, and dose escalation with biologics in inflammatory bowel disease in the United States. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S87-8. doi: 10.1016/j.jval.2018.04.582

Levine C, Ansquer V, Kurosky SK. Factors associated with data collection duration and participation rates in retrospective noninterventional medical record review studies. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 21, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl):S219. doi: 10.1016/j.jval.2018.04.1485

Suzuki C, Lopes N, Tozato C, Gilloteau I, Graham CN. Cost per responder of secukinumab compared to other biologics in moderate-to-severe plaque psoriasis in Brazil. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S240. doi: 10.1016/j.jval.2018.04.1633

Bhaila R, Purser M, Hartley L. Framework for systematic review of cost and resource use studies. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 21, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S52. doi: 10.1016/j.jval.2018.04.438

Vass C, Rigby D, Payne K. Investigating the heterogeneity in women's preferences for breast screening: does the communication of risk matter? Value Health. 2018 Feb;21(2018):219-28. doi: 10.1016/j.jval.2017.07.010

Rowen D, Stevens K, Labeit A, Elliott J, Mulhern B, Carlton J, Basarir H, Ratcliffe J, Brazier J. Using a discrete choice experiment involving cost to value a classification system measuring the quality-of-life impact of self-management for diabetes. Value Health. 2018 Jan;21(1):69-77. doi: 10.1016/j.jval.2017.06.016

Ainsworth CM, Vickers AD, Le Moine J. Assessing the robustness of network meta-analysis of atypical antipsychotics in the presence of heterogeneity. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 8, 2017. Glasgow, Scotland. [abstract] Value Health. 2017 Oct; 20(9):A767. doi: 10.1016/j.jval.2017.08.2189

Grimes R, Grant L, Kaur S, Spencer H, Brookes B, Bennett B. Evaluating patient reported outcomes commonly used in current lung cancer clinical trials. Value Health. 2017 Oct 1;20(9):PA764.

Dong OM, Borse MS, Polasek MJ, Farley JF, Stouffer GA, Lee CR. CYP2C19 guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and one year outcomes following percutaneous coronary intervention. Presented at the 2017 ISPOR 20th Annual European Congress; November 6, 2017. Glasgow, Scotland. [abstract] Value Health. 2017 Oct 1; 20(9):A405. doi: 10.1016/j.jval.2017.08.041

Sluga-O'Callaghan M, Ansquer V, Frugier G, Mai C. Regulatory requirements for non-interventional studies collecting patient preferences and experiences in France, Germany and the UK. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 2017. Glasgow, Scotland. [abstract] Value Health. 2017 Oct; 20(9):A707.

Bonner N, Hall R, Tritton T, Grimes R, Trennery C, Spencer H, Bennett B. Rare diseases, are caregivers just as affected as patients? Value Health. 2017 Oct 1;20(9):PA562.

Spencer H, Grant L, Kaur S, Grimes R, Brookes B, Bennett B. Special considerations for conducting qualitative interviews with cancer patients and their caregivers for the purpose of developing clinical outcome assessments. Poster presented at the 2017 ISPOR 20th Annual European Conference; November 2017. Glasgow, Scotland. [abstract] Value Health. 2017 Oct; 20(9):A777. doi: 10.1016/j.jval.2017.08.2247

Dong O, Li A, Suzuki O, Oni-Orisan A, Stouffer GA, Lee CR, Wiltshire T. Projected impact of adopting a multiplexed preemptive genotyping intervention in cardiac catheterization laboratory patients. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May 1; 20(5):A276.

Talbird SE, La EM, Mauskopf J, Krueger WS, Altland A, Daniels VJ, Pillsbury M, Wolfson LJ. Modeling the impact of exogenous boosting on herpes zoster: an updated methodological review of the varicella zoster virus literature. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A325.

Talbird SE, La EM, Poston SA, Hogea CS. A budget-impact analysis of quadrivalent influenza vaccine use in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A73.

Stull DE, Houghton K, Ainsworth C, Price G, Boye ME. The effects of disease and treatment-associated cancer symptoms on health-related quality-of-life: the mediating effect of fatigue in non-small cell lung cancer and metastatic breast cancer. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A121.

Kurosky S, Lorenzo M, Cuyun Carter G, Parikh RC, Winfree K, Kaye JA. Health care resource utilization and costs of metastatic non-small cell lung cancer in select European countries. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A361.

Svedsater H, Doward L, Whalley D, Crawford R, Leather D, Lay-Flurrie J, Bosanquet N. Salford Lung Study in Chronic Obstructive Pulmonary Disease (SLS COPD): follow-up interviews on patient-centered outcomes. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A205.

Ajmera MR, Goyal RK, Davis KL. Incremental economic burden of cardiometabolic disorders among patients with epilepsy. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A191.

Graham CN, Mcbride D, Miles L, Gilloteau I, O'Neill CB, Neidhardt K, Augustin M. Cost-effectiveness of secukinumab in moderate to severe psoriasis compared with other biologics in Germany. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A157.

Augustin M, Graham CN, Miles L, Gilloteau I, O'Neill CB, Neidhardt K, Mcbride D. A cost-per-responder analysis of secukinumab compared with ustekinumab through 52 weeks in Germany: results from the clear study of patients with moderate to severe psoriasis. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A158.

Sabar U, Rycroft C, Ronquest NA, Nadipelli VR, Wollschlaeger B, Akehurst R. Analysis of humanistic burden reveals a need for opioid use disorder (OUD) disease-specific HRQoL instruments. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A300.

Sabar U, Rycroft C, Ronquest NA, Nadipelli VR, Wollschlaeger B, Akehurst R. The economic burden of opioid use disorder (OUD): results of a structured literature review. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A298.

Sluga-O'Callaghan M, Derrien Ansquer V, Mai C. Evolution of regulatory requirements for retrospective observational studies using medical records in France, Germany, Spain and the UK. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(2017):A68.

McLeod L, Sikirica MV, Qin S, Joshi AV, Sweeney CT, Blum SI. Psychometric evaluation of the nausea and vomiting questionnaire in patients with type 2 diabetes mellitus receiving a glucagon-like peptide-1 receptor agonist. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A175.

McLeod L, Sikirica MV, Davenport E, Sweeney CT, Joshi AV. The impact of GLP-1 induced nausea and vomiting on work productivity and health-related quality of life in patients with T2DM. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A172.

Bell K, Meyers J, Candrilli SD, Ajmera MR. Characteristics and costs of patients with type 2 diabetes augmenting metformin with dapagliflozin versus glipizide: an analysis of commercial claims data. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A169.